Go Pro
→ The Starlink of Energy (From Monument Traders Alliance) (Ad)tc pixel
NASDAQ:PLUR

Pluri Q3 2026 Earnings Report

Pluri logo
$2.14 +0.03 (+1.47%)
As of 10:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pluri EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.66
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Pluri Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
$0.66 million
Beat/Miss
Missed by -$488.00 thousand
YoY Revenue Growth
N/A

Pluri Announcement Details

Quarter
Q3 2026
Date
5/14/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Pluri's next earnings date is estimated for Wednesday, September 23, 2026, based on past reporting schedules.

Conference Call Resources

Pluri Earnings Headlines

Analyzing Apollomics (NASDAQ:APLM) and Pluri (NASDAQ:PLUR)
July 3 at 4:49 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30876628
Lab-grown coffee and chocolate could save both industries
June 26, 2026  |  msn.comhttps://www.msn.com/en-us/food-and-drink/beverages/lab-grown-coffee-and-chocolate-could-save-both-industries/ar-AA26wFrR
Elon Musk on His New Invention: “An Infinite Money Glitch.”
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel
July 6 at 1:00 AM  |  Brownstone Research (Ad)
Pluri Secures Insider Advance Subscription to Boost Liquidity
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pluri-secures-insider-advance-subscription-to-boost-liquidity?utm_source=marketbeat.com&utm_medium=referral
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305041/11974/en/pluri-advances-toward-u-s-commercial-launch-through-its-subsidiary-cellav-following-completion-of-regenerative-aesthetic-products-listing.html
Pluri in Good-Faith Talks on EIB Loan Resolution
June 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pluri-in-good-faith-talks-on-eib-loan-resolution?utm_source=marketbeat.com&utm_medium=referral
See More Pluri Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email.

About Pluri

Pluri (NASDAQ:PLUR) (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies. Its PLX cell therapies have been evaluated in clinical studies targeting critical limb ischemia, hematopoietic support following radiation exposure and tissue repair in musculoskeletal injuries. The company has also received grant funding for programs addressing acute radiation syndrome and continues to explore additional indications in immune and inflammatory diseases.

Headquartered in Haifa, Israel, Pluri operates a GMP-certified manufacturing facility capable of supporting commercial-scale production. The company’s global footprint extends to clinical trial sites and partnership agreements in the United States, Europe and the Asia-Pacific region. Pluri’s leadership team brings extensive expertise in regenerative medicine, cellular manufacturing and regulatory affairs as it works toward potential market authorization and broad clinical adoption of its cell therapy products.

View Pluri Profile
Earnings Tools